Literature DB >> 16116599

Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.

Luca Cindolo1, Jean-Jacques Patard, Paolo Chiodini, Luigi Schips, Vincenzo Ficarra, Jacques Tostain, Alexandre de La Taille, Vincenzo Altieri, Bernard Lobel, Richard E Zigeuner, Walter Artibani, François Guillé, Claude C Abbou, Luigi Salzano, Ciro Gallo.   

Abstract

BACKGROUND: The objective of the current study was to compare, in a large multicenter study, the discriminating accuracy of four prognostic models developed to predict the survival of patients undergoing nephrectomy for nonmetastatic renal cell carcinoma (RCC).
METHODS: A total of 2404 records of patients from 6 European centers were retrospectively reviewed. For each patient, prognostic scores were calculated according to four models: the Kattan model, the University of California at Los Angeles integrated staging system (UISS) model, the Yaycioglu model, and the Cindolo model. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. Discriminating ability was assessed by the Harrell c-index for censored data. The primary end point was overall survival (OS), and the secondary end points were cancer-specific survival (CSS) and disease recurrence-free survival (RFS).
RESULTS: At last follow-up, 541 subjects had died of any causes, with a 5-year OS rate of 80%. The 5-year CSS and RFS rates were 85% and 78%, respectively. All models discriminated well (P < 0.0001). The c-indexes for OS were 0.706 for the Kattan nomogram, 0.683 for the UISS model, and 0.589 and 0.615 for the Yaycioglu and Cindolo models, respectively. The Kattan nomogram was found to improve discrimination substantially in the UISS intermediate-risk patients.
CONCLUSIONS: The current study appears to better define the general applicability of prognostic models for predicting survival in patients with nonmetastatic RCC treated with nephrectomy. The results suggest that postoperative models discriminate substantially better than preoperative ones. The Kattan model was consistently found to be the most accurate, although the UISS model was only slightly less well performing. The Kattan model can be useful in the UISS intermediate-risk patients.

Entities:  

Mesh:

Year:  2005        PMID: 16116599     DOI: 10.1002/cncr.21331

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  59 in total

Review 1.  Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).

Authors:  Juan I Martínez-Salamanca; Estefania Linares; Javier González; Roberto Bertini; Joaquín A Carballido; Thomas Chromecki; Gaetano Ciancio; Sia Daneshmand; Christopher P Evans; Paolo Gontero; Axel Haferkamp; Markus Hohenfellner; William C Huang; Theresa M Koppie; Viraj A Master; Rayan Matloob; James M McKiernan; Carrie M Mlynarczyk; Francesco Montorsi; Hao G Nguyen; Giacomo Novara; Sascha Pahernik; Juan Palou; Raj S Pruthi; Krishna Ramaswamy; Oscar Rodriguez Faba; Paul Russo; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; Derya Tilki; Daniel Vergho; Eric M Wallen; Evanguelos Xylinas; Richard Zigeuner; John A Libertino
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

2.  Preoperative nomogram predicting 12-year probability of metastatic renal cancer.

Authors:  Ganesh V Raj; R Houston Thompson; Bradley C Leibovich; Michael L Blute; Paul Russo; Michael W Kattan
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

3.  [Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years].

Authors:  M May; F Kendel; B Hoschke; C Gilfrich; S Kiessig; S Pflanz; M Seidel; S Brookman-Amissah
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

4.  A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use.

Authors:  Christian Beisland; Gigja Guðbrandsdottir; Lars A R Reisæter; Leif Bostad; Karin M Hjelle
Journal:  World J Urol       Date:  2016-02-27       Impact factor: 4.226

Review 5.  Prognostic factors in renal cell carcinoma.

Authors:  Alessandro Volpe; Jean Jacques Patard
Journal:  World J Urol       Date:  2010-04-03       Impact factor: 4.226

Review 6.  Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.

Authors:  Jacqueline M Speed; Quoc-Dien Trinh; Toni K Choueiri; Maxine Sun
Journal:  Curr Urol Rep       Date:  2017-02       Impact factor: 3.092

Review 7.  Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients.

Authors:  Tracy M Downs; Matthew Schultzel; Helen Shi; Catherine Sanders; Zunera Tahir; Georgia Robins Sadler
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-06       Impact factor: 6.312

8.  External validation of the preoperative Karakiewicz nomogram in a large multicentre series of patients with renal cell carcinoma.

Authors:  Paolo Gontero; Maxine Sun; Alessandro Antonelli; Roberto Bertini; Marco Carini; Giorgio Carmignani; Nicola Longo; Giuseppe Martorana; Andrea Minervini; Vincenzo Mirone; Giuseppe Morgia; Giacomo Novara; Marco Oderda; Claudio Simeone; Alchiede Simonato; Salvatore Siracusano; Alessandro Tizzani; Alessandro Volpe; Pierre Karakiewicz; Vincenzo Ficarra
Journal:  World J Urol       Date:  2012-07-31       Impact factor: 4.226

9.  The association between statin medication and progression after surgery for localized renal cell carcinoma.

Authors:  Robert J Hamilton; Daniel Morilla; Fernando Cabrera; Michael Leapman; Ling Y Chen; Melanie Bernstein; A Ari Hakimi; Victor E Reuter; Paul Russo
Journal:  J Urol       Date:  2013-11-26       Impact factor: 7.450

10.  Risk Based Surveillance after Surgical Treatment of Renal Cell Carcinoma.

Authors:  Paolo Capogrosso; Alessandro Larcher; Daniel D Sjoberg; Emily A Vertosick; Francesco Cianflone; Paolo Dell'Oglio; Cristina Carenzi; Andrea Salonia; Andrew J Vickers; Francesco Montorsi; Roberto Bertini; Umberto Capitanio
Journal:  J Urol       Date:  2018-01-31       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.